Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Dermatologic 2Sarcoma 1

Conditions

Hodgkin Disease 27Lymphoma 22Hematologic Diseases 20Lymphoma, Large-Cell, Anaplastic 16Lymphoma, Non-Hodgkin 11Recurrence 5Lymphoma, T-Cell, Peripheral 5Lymphoma, T-Cell 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma, B-Cell 4Lymphoma, T-Cell, Cutaneous 3Squamous Cell Carcinoma of Head and Neck 2Neoplasms 2Melanoma 2Lymphoma, Primary Cutaneous Anaplastic Large Cell 2Dendritic Cell Sarcoma, Interdigitating 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Sarcoma, Kaposi 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Neoplasms by Histologic Type 1Myelodysplastic Syndromes 1Mycosis Fungoides 1Lymphoproliferative Disorders 1Lymphomatoid Papulosis 1

Interventions

Brentuximab Vedotin 2Bexarotene 2iratumumab 1Vitamin B 12 1Methotrexate 1Folic Acid 110-propargyl-10-deazaaminopterin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, Primary Cutaneous Anaplastic Large Cell × Brentuximab Vedotin × Clear all
NCT01578499 2021-01-05

ALCANZA

Takeda

Phase 3 Completed
131 enrolled 24 charts
DermatologicLymphoid

Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphoma, Primary Cutaneous Anaplastic Large Cell

NCT00099255 2014-12-18

Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma

Seagen Inc.

Phase 2 Completed
40 enrolled
DermatologicLymphoidSarcoma

Lymphomatoid Papulosis, Lymphoma, Primary Cutaneous Anaplastic Large Cell, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡